U.S. Markets closed

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.71-0.55 (-3.86%)
At close: 4:00PM EST
Sign in to post a message.
  • s
    read Saturday company news release 6 for 6 at average 82 weeks . No injections . This is a group that had many dozens a year and now none at 82 weeks that is showing durability .
    If this is a cure for millions and they can price in correctly so medicare/medicaid and insurance will pay this is a multi billion dollar therapy. Do not want to hype but really the media should be looking at this . It is gonna be great if they repeat in a pivotal large study .
  • 8
    Institutional accumulation pattern on yesterday's buys with million dollar purchase at the bell
  • A
    Pivotal trial starts 2021 with multiple other trials ongoing..
    Clinical hold lifted..
    Company has lots of cash to move this forward with its recent cash raise..
  • 8
    Wow retail investors oblivious to this
    Stock?!! I believe institutions want it that way as 90% ownership in place . There should be significant pop after that stellar update. Analysts seemed extremely excited but nobody but tutes knows it exists
  • 8
    Clinical update excellent. Presenters knocked it out of ball park
  • L
    From what I have researched, the therapy seems to be working very well, especially with the single dose that allows for total compliance without the need to go for monthly injections. My question, which maybe we can learn more from the conferences and er, is a timetable to possible commercialization. With the length of the present trial as an example, we could be maybe 2-3 years away before filing if trial results continue to show promise. Does anyone have an opinion on this that they would like to explain and share? Thanks for all input and I will continue to see if I can find anything on projected timelines. GLTA.
  • s
    for company to post so early concerning an update on trial due in mid nov . it must be such good news they simply can not hold back . they need to make it known without actually releasing the known news.
  • A
    No posts. Everyone out now ? May be time to buy. Either a problem in the trial or this thing is wayyyyyyy oversold. Im buying a few. GLTA
  • s
    someone liked the presentation today on 11/23 up 7 percent . The word is getting out . This should be in the 20 s
  • F
    100 million public offering at how much a share I see this go both ways opion is it a good or bad thing.
  • K
    Kevin McMullen
    very interested in todays ceo keynote in Boston, should be a great week for advm investors.
  • N
    like getting 1/6 of entire company through a pinhole to cover shorts. regeneron has increased partnership with 7 new partnered programs with ADVERUM. Updated on website
  • J
    What a manipulation. Read the news:
    One of the most extreme valuations belongs to Adverum Biotechnologies Inc. (NASDAQ:ADVM) of Redwood City, California, which is working on several forms of gene therapy for ocular and rare diseases. It sells for more than 3,000 times revenue.

    According to its website, Adverum has one drug in Phase 1 clinical trials and two drugs in preclinical trials (animal testing).

    For the moment, annual revenue is about $320,000 while the stock's market value is about $1 billion.
  • H
    Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiencyhttps://finance.yahoo.com/news/adverum-biotechnologies-announces-completion-dosing-140000701.html
  • k
    Surpasses Wall Street expectation by .02 cents , that’s good news... now let’s roll !!
  • S
    Company has no sales channel, operates under NOL every year, can only raise capital by diluting shares/raising debt, has 3 years of cash left with no product, and is about to dilute its shareholders by over $6/share and people are buying it? So bizarre.
  • i
    Editas (EDIT) is using Adverums AAV's in their own CRISPR ocular trials with a 3 month readout coming soon. I own both.
  • W
    reasonable price: about $9
  • d
    Tomorrow is going to be a great day 👍
  • K
    There is tremendous interest in this drug by Regeneron. They already are shareholder and it is in best interests for nuyout at about 1.5 x highest sp in last 6 months or 1.5x $16.66+ $29-30. Sounds good as Regeneron needs to protect their 10 Billion a year Eyelea franchise and medicine is moving to gene therapy as cure. ADVM has 100 % results at week 42 already on Clinicalgovtrials website. Rare to get second chance down here.